Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440277 | 0.86 | MEN1 (0.56) | MEN1KMT2ASIRT6MAPTHRH3 | |
| SCHEMBL10118638 | 0.86 | MEN1 (0.53) | MEN1KMT2ASIRT6MAPTHRH3 | |
| SCHEMBL7293302 | 0.85 | SIRT6 (0.52) | MEN1KMT2ASIRT6MAPTHRH3 | |
| SCHEMBL3441322 | 0.84 | MAPT (0.50) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL7300716 | 0.82 | MEN1 (0.50) | MEN1KMT2ASIRT6MAPTHRH3 | |
| SCHEMBL21245530 | 0.81 | MAPT (0.60) | MEN1KMT2AMAPTHRH3POLB | |
| SCHEMBL25189631 | 0.81 | MEN1 (0.60) | MEN1KMT2ASIRT6MAPTHRH3 | |
| SCHEMBL27832 | 0.81 | SIRT6 (0.59) | MEN1KMT2ASIRT6MAPTHRH3 | |
| SCHEMBL3440216 | 0.81 | MAPT (0.59) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL30981311 | 0.80 | MAPT (0.58) | MEN1KMT2ASIRT6MAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142748-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| EP-4008719-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2022-06-08 | — | — | EP | disclosed |
| CN-112142748-A | Pyrazolone pyrimidine compound, preparation method and application thereof | 上海医药集团股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | WEE1, WEE2, WASF2 | MEN1 1281/4885KMT2A 2683/4885SIRT6 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.